Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Next Previous
Trial Profile

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimesna (Primary) ; Carboplatin; Pemetrexed
  • Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms HARMONIC; Harmonica
  • Sponsors Lantern Pharma

Most Recent Events

  • 13 Nov 2025 According to a Lantern Pharma media release,preliminary Phase 2 data from this trial presented at at the 66th Annual Meeting of the Japan Lung Cancer Society with further clinical and patient data planned for a webinar in December.
  • 13 Aug 2025 According to a Lantern Pharma media release,Additional data and clinical findings from this trial anticipated in September 2025, including initial response and safety evaluations for patients from the Asian expansion cohort enrolled across sites in Japan and Taiwan.
  • 31 Jul 2025 According to a Lantern Pharma media release, Additional clinical data and updates from the US and Asian patient cohorts is expected by the end of the third quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top